keyword
https://read.qxmd.com/read/38652598/notch1-hyperactivity-drives-ubiquitination-of-nox2-and-dysfunction-of-cd8-regulatory-t-cells-in-patients-with-systemic-lupus-erythematosus
#1
JOURNAL ARTICLE
Zixin Yuan, Mengdi Liu, Lei Zhang, Li Jia, Siao Hao, Danhua Su, Longhai Tang, Chunhong Wang, Mingyuan Wang, Zhenke Wen
OBJECTIVES: Patients with systemic lupus erythematosus (SLE) display heightened immune activation and elevated IgG autoantibody levels, indicating compromised regulatory T cell (Tregs) function. Our recent findings pinpoint CD8+ Tregs as crucial regulators within secondary lymphoid organs, operating in a NOX2-dependent mechanism. However, the specific involvement of CD8+ Tregs in SLE pathogenesis and the mechanisms underlying their role remain uncertain. METHODS: SLE and healthy individuals were enlisted to assess the quantity and efficacy of Tregs...
April 23, 2024: Rheumatology
https://read.qxmd.com/read/38652192/bortezomib-suppresses-acute-myelogenous-leukaemia-stem-like-kg-1a-cells-via-nf-%C3%AE%C2%BAb-inhibition-and-the-induction-of-oxidative-stress
#2
JOURNAL ARTICLE
Rafaela G A Costa, Maiara de S Oliveira, Ana Carolina B da C Rodrigues, Suellen L R Silva, Ingrid R S B Dias, Milena B P Soares, Ludmila de Faro Valverde, Clarissa Araujo Gurgel Rocha, Rosane Borges Dias, Daniel P Bezerra
Acute myelogenous leukaemia (AML) originates and is maintained by leukaemic stem cells (LSCs) that are inherently resistant to antiproliferative therapies, indicating that a critical strategy for overcoming chemoresistance in AML therapy is to eradicate LSCs. In this work, we investigated the anti-AML activity of bortezomib (BTZ), emphasizing its anti-LSC potential, using KG-1a cells, an AML cell line with stem-like properties. BTZ presented potent cytotoxicity to both solid and haematological malignancy cells and reduced the stem-like features of KG-1a cells, as observed by the reduction in CD34- and CD123-positive cells...
April 2024: Journal of Cellular and Molecular Medicine
https://read.qxmd.com/read/38650933/eltrombopag-can-promote-platelet-implantation-after-allogeneic-hematopoietic-stem-cell-transplantation-as-safely-and-similarly-to-thrombopoietin
#3
JOURNAL ARTICLE
Yahan Li, Fansheng Kong, Guanchen Bai, Yujie Jiang, Wenlu Zhang, Xue Sun, Xiaohui Sui, Ying Li, Mei Ding, Dai Yuan, Xin Wang, Xiaosheng Fang
BACKGROUND: Eltrombopag has demonstrated efficacy in treating low platelet (PLT) levels, but it remains unclear whether eltrombopag can promote PLT engraftment after hematopoietic stem cell transplantation (HSCT). METHODS: Forty-one HSCT patients received eltrombopag 50 mg/d from +1 day until PLT >50 × 109 /L or 1 month after HSCT. Fifty-one patients in the same period received thrombopoietin (TPO) to promote PLT graft after HSCT and served as a control group...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38647418/therapeutic-efficacy-of-ras-inhibitor-trametinib-using-a-juvenile-myelomonocytic-leukemia-patient-derived-xenograft-model
#4
JOURNAL ARTICLE
Alex Q Lee, Hiroaki Konishi, Masami Ijiri, Yueju Li, Arun Panigrahi, Jeremy Chien, Noriko Satake
Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric leukemia with few effective treatments and poor outcomes even after stem cell transplantation, the only current curative treatment. We developed a JMML patient-derived xenograft (PDX) mouse model and demonstrated the in vivo therapeutic efficacy and confirmed the target of trametinib, a RAS-RAF-MEK-ERK pathway inhibitor, in this model. A PDX model was created through transplantation of patient JMML cells into mice, up to the second generation, and successful engraftment was confirmed using flow cytometry...
April 22, 2024: Pediatric Hematology and Oncology
https://read.qxmd.com/read/38647328/three-dimensional-cell-culture-of-adipose-derived-stem-cells-in-a-hydrogel-with-photobiomodulation-augmentation
#5
JOURNAL ARTICLE
Brendon Roets, Heidi Abrahamse, Anine Crous
Adipose-derived stem cells (ADSCs), possessing multipotent mesenchymal characteristics akin to stem cells, are frequently employed in regenerative medicine due to their capacity for a diverse range of cell differentiation and their ability to enhance migration, proliferation, and mitigate inflammation. However, ADSCs often face challenges in survival and engraftment within wounds, primarily due to unfavorable inflammatory conditions. To address this issue, hydrogels have been developed to sustain ADSC viability in wounds and expedite the wound healing process...
April 5, 2024: Journal of Visualized Experiments: JoVE
https://read.qxmd.com/read/38645184/car-tregs-mediate-linked-suppression-and-infectious-tolerance-in-islet-transplantation
#6
Christine M Wardell, Vivian C W Fung, Eleanor Chen, Manjurul Haque, Jana Gillies, Justin A Spanier, Majid Mojibian, Brian T Fife, Megan K Levings
UNLABELLED: Regulatory T cells (Tregs) have potential as a cell-based therapy to prevent or treat transplant rejection and autoimmunity. Using an HLA-A2-specific chimeric antigen receptor (A2-CAR), we previously showed that adoptive transfer of A2-CAR Tregs limited anti-HLA-A2 alloimmunity. However, it was unknown if A2-CAR Tregs could also limit immunity to autoantigens. Using a model of HLA-A2 + islet transplantation into immunodeficient non-obese diabetic mice, we investigated if A2-CAR Tregs could control diabetes induced by islet-autoreactive (BDC2...
April 10, 2024: bioRxiv
https://read.qxmd.com/read/38644499/graft-failure-after-allogeneic-hematopoietic-stem-cell-transplantation-in-pediatric-patients-with-acute-leukemia-autologous-reconstitution-or-second-transplant
#7
REVIEW
Tahereh Rostami, Mohammad Reza Rostami, Amir Hossein Mirhosseini, Saeed Mohammadi, Mohsen Nikbakht, Hediyeh Alemi, Naghmeh Khavandgar, Soroush Rad, Ghasem Janbabai, Seied Asadollah Mousavi, Azadeh Kiumarsi, Amir Kasaeian
BACKGROUND: Graft failure (GF) is a rare but serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). Prevention of graft failure remains the most advisable approach as there is no clear recommendation for the best strategies for reversing this complication. Administration of growth factor, additional hematopoietic progenitor boost, or a salvage HSCT are current modalities recommended for the treatment of GF. Autologous recovery without evidence of disease relapse occurs rarely in patients with GF, and in the absence of autologous recovery, further salvage transplantation following a second conditioning regimen is a potential treatment option that offers the best chances of long-term disease-free survival...
April 22, 2024: Stem Cell Research & Therapy
https://read.qxmd.com/read/38641011/lymphocyte-crossmatch-testing-or-donor-hla-dp-and-dq-allele-typing-effectiveness-in-single-cord-blood-transplantation-for-patients-with-anti-hla-antibodies-other-than-against-hla-a-b-c-and-drb1
#8
JOURNAL ARTICLE
Makoto Osada, Hisashi Yamamoto, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Shigeyoshi Makino, Yuki Asano-Mori, Go Yamamoto, Shuichi Taniguchi, Atsushi Wake, Naoyuki Uchida
Anti-human leukocyte antigen (HLA) antibodies other than those against HLA-A, -B, -C, and DRB1 are a risk factor for engraftment delay and failure, especially in cord blood transplantation (CBT) OBJECTIVES: The primary objective of this study was to assess the impact of the presence of anti-HLA antibodies on CBT and to evaluate the utility of lymphocyte crossmatch testing or additional HLA-DP and HLA-DQ typing of CB units in improving transplant outcomes STUDY DESIGN: We retrospectively assessed the engraftment rates and transplant outcomes of 772 patients who underwent their first CBT at our hospital between 2012 and 2021...
April 17, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38634530/soft-tissue-augmentation-around-dental-implants-by-a-new-laser-aided-pouch-roll-technique-volumetric-and-clinical-evaluation-after-1-year
#9
JOURNAL ARTICLE
Marco Giannelli, Matteo Pinzani, Luca Lorenzini, Tiziana Fossi, Daniele Bani
The ultimate goal in implantology is to restore the whole tooth-gingival complex in a fashion that cannot be distinguished from the rest of the natural dentition. This study assesses the volumetric and clinical changes of vestibular gingival soft tissues, crucial for satisfactory engraftment and aesthetic results, upon treatment with laser-aided pouch roll augmentation in second-stage surgery for dental implant uncovering. Twelve patients with mild ridge deficiencies in 16 edentulous sites, including distal elements, were enrolled and re-evaluated for up to 1 year...
April 18, 2024: Journal of Oral Implantology
https://read.qxmd.com/read/38634344/neutrophil-antigen-antibodies-affect-engraftment-and-secondary-graft-failure-in-hematopoietic-progenitor-cell-transplantation
#10
JOURNAL ARTICLE
Abdullah Alswied, Sajjad Hassan, Herleen Rai, Willy Albert Flegel
BACKGROUND: Research is limited on the role of antibodies against human neutrophil antigen (HNA) in hematopoietic progenitor cell (HPC) transplantation outcomes. STUDY DESIGN AND METHODS: A retrospective review was conducted on medical records of patients at the NIH Clinical Center enrolled in six research protocols. This case-control study included 21 patients tested for HNA antibodies from January 2010 to March 2022 who underwent HPC transplantation. In addition, 42 patients following the same research protocols were randomly selected as a control group...
April 18, 2024: Transfusion
https://read.qxmd.com/read/38633119/graft-versus-host-disease-after-autologous-stem-cell-transplantation-in-a-recipient-who-underwent-allogeneic-stem-cell-transplantation-20-years-earlier
#11
JOURNAL ARTICLE
Osamu Imataki, Shunsuke Yoshida, Tomoya Ishida, Haruyuki Fujita, Makiko Uemura
A literature review does not provide information about the safety of autologous hematopoietic stem cell transplantation (HSCT) in a recipient who has previously received allogeneic HSCT. We treated a 69-year-old woman with diffuse large B cell lymphoma. The patient received autologous stem cell transplantation (ASCT) in the second complete remission of malignant lymphoma. The patient had undergone allogeneic hematopoietic SCT (allo-HSCT) for chronic myeloid leukemia 20 years ago. Chronic myeloid leukemia had been in complete remission for the previous 20 years...
April 2024: EJHaem
https://read.qxmd.com/read/38632504/metabolic-difference-between-patient-derived-xenograft-model-of-pancreatic-ductal-adenocarcinoma-and-corresponding-primary-tumor
#12
JOURNAL ARTICLE
Shi Wen, Xianchao Lin, Wei Luo, Yu Pan, Fei Liao, Zhenzhao Wang, Bohan Zhan, Jianghua Feng, Heguang Huang
BACKGROUND: Patients-derived xenograft (PDX) model have been widely used for tumor biological and pathological studies. However, the metabolic similarity of PDX tumor to the primary cancer (PC) is still unknown. METHODS: In present study, we established PDX model by engrafting primary tumor of pancreatic ductal adenocarcinoma (PDAC), and then compared the tumor metabolomics of PC, the first generation of PDX tumor (PDXG1), and the third generation of PDX tumor (PDXG3) by using 1 H NMR spectroscopy...
April 17, 2024: BMC Cancer
https://read.qxmd.com/read/38631714/efficacy-of-lcmv-based-cancer-immunotherapies-is-unleashed-by-intratumoral-injections-of-polyi-c
#13
JOURNAL ARTICLE
Celia Gomar, Claudia Augusta Di Trani, Angela Bella, Leire Arrizabalaga, Jose Gonzalez-Gomariz, Myriam Fernandez-Sendin, Maite Alvarez, Joan Salvador Russo-Cabrera, Nuria Ardaiz, Fernando Aranda, Timo Schippers, Marisol Quintero, Ignacio Melero, Klaus K Orlinger, Henning Lauterbach, Pedro Berraondo
BACKGROUND: Lymphocytic choriomeningitis virus (LCMV) belongs to the Arenavirus family known for inducing strong cytotoxic T-cell responses in both mice and humans. LCMV has been engineered for the development of cancer immunotherapies, currently undergoing evaluation in phase I/II clinical trials. Initial findings have demonstrated safety and an exceptional ability to activate and expand tumor-specific T lymphocytes. Combination strategies to maximize the antitumor effectiveness of LCMV-based immunotherapies are being explored...
April 16, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38629183/a-comparative-review-of-aphexda-and-mozobil-for-mobilization-prior-to-stem-cell-collection
#14
REVIEW
Lauren Dietz, Jessica Marini, Hamza Hashmi, Mary McGann
High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation is the standard of care for eligible patients with newly diagnosed multiple myeloma leading to prolonged progression free and overall survival. Successful engraftment following hematopoietic stem cell infusion requires adequate stem cell doses. Current mobilization regimens include granulocyte colony-stimulating factor (G-CSF) with or without plerixafor. Motixafortide is a recently approved agent that can be used in combination with G-CSF for mobilization...
April 17, 2024: Journal of Oncology Pharmacy Practice
https://read.qxmd.com/read/38626772/osteopontin-drives-neuroinflammation-and-cell-loss-in-mapt-n279k-frontotemporal-dementia-patient-neurons
#15
JOURNAL ARTICLE
Osama Al-Dalahmah, Matti Lam, Julie J McInvale, Wenhui Qu, Trang Nguyen, Jeong-Yeon Mun, Sam Kwon, Nkechime Ifediora, Aayushi Mahajan, Nelson Humala, Tristan Winters, Ellen Angeles, Kelly A Jakubiak, Rebekka Kühn, Yoon A Kim, Maria Caterina De Rosa, Claudia A Doege, Fahad Paryani, Xena Flowers, Athanassios Dovas, Angeliki Mela, Hong Lu, Michael A DeTure, Jean Paul Vonsattel, Zbigniew K Wszolek, Dennis W Dickson, Tanja Kuhlmann, Holm Zaehres, Hans R Schöler, Andrew A Sproul, Markus D Siegelin, Philip L De Jager, James E Goldman, Vilas Menon, Peter Canoll, Gunnar Hargus
Frontotemporal dementia (FTD) is an incurable group of early-onset dementias that can be caused by the deposition of hyperphosphorylated tau in patient brains. However, the mechanisms leading to neurodegeneration remain largely unknown. Here, we combined single-cell analyses of FTD patient brains with a stem cell culture and transplantation model of FTD. We identified disease phenotypes in FTD neurons carrying the MAPT-N279K mutation, which were related to oxidative stress, oxidative phosphorylation, and neuroinflammation with an upregulation of the inflammation-associated protein osteopontin (OPN)...
April 10, 2024: Cell Stem Cell
https://read.qxmd.com/read/38621815/tetracyclines-enhance-antitumor-t-cell-immunity-via-the-zap70-signaling-pathway
#16
JOURNAL ARTICLE
Mari Tone, Kota Iwahori, Michinari Hirata, Azumi Ueyama, Akiyoshi Tani, Jun-Ichi Haruta, Yoshito Takeda, Yasushi Shintani, Atsushi Kumanogoh, Hisashi Wada
BACKGROUND: Cancer immunotherapy including immune checkpoint inhibitors is only effective for a limited population of patients with cancer. Therefore, the development of novel cancer immunotherapy is anticipated. In preliminary studies, we demonstrated that tetracyclines enhanced T-cell responses. Therefore, we herein investigated the efficacy of tetracyclines on antitumor T-cell responses by human peripheral T cells, murine models, and the lung tumor tissues of patients with non-small cell lung cancer (NSCLC), with a focus on signaling pathways in T cells...
April 15, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38619277/in-vivo-imaging-of-liver-spheroids-engrafted-in-the-anterior-chamber-of-the-mouse-eye
#17
JOURNAL ARTICLE
Francesca Lazzeri-Barcelo, Pierpaolo Ciardo, Barbara Leibiger, Ingo B Leibiger, Per-Olof Berggren, Noah Moruzzi
Biomedical studies of the liver in mammals are hindered by the lack of methods for in vivo noninvasive longitudinal imaging at cellular resolution. Until now, optical imaging of the liver in situ is possible by intravital imaging, which offers high-resolution imaging at the cellular level but cannot be performed multiple times and, therefore, longitudinally in the same animal. Noninvasive imaging methods, such as bioluminescence, allow repeated imaging sessions on the same animal but do not achieve cell resolution...
March 29, 2024: Journal of Visualized Experiments: JoVE
https://read.qxmd.com/read/38617334/cas9-rnp-physiochemical-analysis-for-enhanced-crispr-aunp-assembly-and-function
#18
Daniel D Lane, Karthikeya S V Gottimukkala, Rachel A Cunningham, Shirley Jwa, Molly E Cassidy, Jack M P Castelli, Jennifer E Adair
CRISPR therapy for hematological disease has proven effective for transplant dependent beta thalassemia and sickle cell anemia, with additional disease targets in sight. The success of these therapies relies on high rates of CRISPR-induced double strand DNA breaks in hematopoietic stem and progenitor cells (HSPC). To achieve these levels, CRISPR complexes are typically delivered by electroporation ex vivo which is toxic to HSPCs. HSPCs are then cultured in stimulating conditions that promote error-prone DNA repair, requiring conditioning with chemotherapy to facilitate engraftment after reinfusion...
April 2, 2024: bioRxiv
https://read.qxmd.com/read/38615283/linc-nsc-affects-cell-differentiation-apoptosis-and-proliferation-in%C3%A2-mouse%C3%A2-neural%C3%A2-stem-cells-and-embryonic-stem-cells-in-vitro-and-in-vivo
#19
JOURNAL ARTICLE
Lili Guo, Dan Zou, Wenqiao Qiu, Fan Fei, Lihua Chen, Wenjin Chen, Huan Xiong, Xinda Li, Yangyang Wang, Mingjun Gao, Jianwei Zhu, Jin Zhang, Yunsen He, Mou Gao, Ruxiang Xu
BACKGROUND: Stem cell therapy is a promising therapeutic strategy. In a previous study, we evaluated tumorigenicity by the stereotactic transplantation of neural stem cells (NSCs) and embryonic stem cells (ESCs) from experimental mice. Twenty-eight days later, there was no evidence of tumor formation or long-term engraftment in the NSCs transplantation group. In contrast, the transplantation of ESCs caused tumor formation; this was due to their high proliferative capacity...
April 14, 2024: Cellular and Molecular Life Sciences: CMLS
https://read.qxmd.com/read/38613166/good-engraftment-after-reduced-intensity-targeted-busulfan-based-conditioning-and-matched-related-donor-hematopoietic-cell-transplantation-in-hemoglobinopathies
#20
JOURNAL ARTICLE
Maximilian Klink, Matthias Felber, Ulrike Zeilhofer, Mathias Hauri-Hohl, Markus Schmugge, Daniel Drozdov, Tayfun Güngör
BACKGROUND: Hematopoietic cell transplantation (HCT) is an established curative therapy for transfusion-dependent thalassemia (TDT) and sickle cell disease (SCD). The latest American Society of Hematology guidelines recommend myeloablative preparative regimen in patients under 18 years of age. PROCEDURE: The objective was to demonstrate safety and efficacy of a reduced intensity conditioning (RIC) regimen including high-dose fludarabine, anti-thymocyte globulin, and targeted busulfan as a single alkylator to sub-myeloablative exposures...
April 12, 2024: Pediatric Blood & Cancer
keyword
keyword
14615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.